Arena Pharma (ARNA) Misses Q2 EPS by 1c

August 8, 2016 4:04 PM EDT
Get Alerts ARNA Hot Sheet
Trade ARNA Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Arena Pharma (NASDAQ: ARNA) reported Q2 EPS of ($0.11), $0.01 worse than the analyst estimate of ($0.10). Revenue for the quarter came in at $9.5 million versus the consensus estimate of $10.44 million.

2016 Corporate Guidance Update

  • R&D expenses between $78 to $84 million, including non-cash expenses of approximately $9 million
  • G&A expenses between $27 to $33 million, including non-cash expenses of approximately $7 million
  • The Company believes the costs reductions and strategic shift in priorities will allow it to manage its cash through completion of Phase 2 clinical trials for its three internal clinical stage programs.

For earnings history and earnings-related data on Arena Pharma (ARNA) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Earnings, Guidance

Related Entities

Earnings

Add Your Comment